Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27534986 | 0.90 | — | — | |
| Urea SCHEMBL28943102 | 0.87 | TSHR (0.35) | TSHR | |
| SCHEMBL6752694 | 0.84 | TSHR (0.40) | TSHR | |
| SCHEMBL11010126 | 0.80 | DNM1 (0.47) | TSHR | |
| SCHEMBL2623214 | 0.78 | — | — | |
| SCHEMBL35990 | 0.77 | — | — | |
| SCHEMBL8062567 | 0.76 | — | — | |
| SCHEMBL1230295 | 0.76 | — | — | |
| SCHEMBL6273275 | 0.75 | DNM1 (0.42) | TSHR | |
| Urea SCHEMBL28950349 | 0.74 | TSHR (0.46) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713615-B2 | Process for producing erythromycin derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | claimed |
| US-20030191295-A1 | Process for producing erythromycin derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-09 | — | — | US | claimed |
| EP-1310506-A1 | PROCESS FOR PRODUCING ERYTHROMYCIN DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-05-14 | — | — | EP | claimed |
| JP-57038703-A | — | — | None | — | — | JP | disclosed |
| US-6713615-B2 | Process for producing erythromycin derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030191295-A1 | Process for producing erythromycin derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1310506-A1 | PROCESS FOR PRODUCING ERYTHROMYCIN DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| JP-S5738703-A | SOIL-STERILIZING AGENT | KANESHO KK | 1982-03-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191295-A1 | Process for producing erythromycin derivative | CYP51A1, ERG28, ELOVL6 | TSHR 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.